---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-000247"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2024-01-02T23:59:59+00:00"
generated_at: "2026-06-07T05:04:37.973743+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Court finds Teva does not infringe Corcept's Korlym patents; Corcept plans appeal

## Summary
- District of New Jersey ruled Teva does not infringe Corcept's U.S. Patents 10,195,214 and 10,842,800.
- Patents cover methods of safely administering Korlym with strong CYP3A4 inhibitors.
- CEO Joseph Belanoff called decision disappointing and based on legal and factual errors.
- Corcept will pursue a vigorous appeal; believes patents expanded treatment options for Cushing's syndrome.
- FDA had added the patented methods to Korlym's prescribing instructions.

## SEC filing metadata
- accession: 0001193125-24-000247
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2024-01-02T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000119312524000247/0001193125-24-000247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000119312524000247/d676865d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-000247
- JSON: https://secwatch.observer/filing/0001193125-24-000247.json
- Plain text: https://secwatch.observer/filing/0001193125-24-000247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.